MedTrace Logo

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

NCT00494533 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2014-01-29

No results posted yet for this study

Summary

Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human immunodeficiency virus (HIV) infection or collagen vascular disease).

Conditions

Interventions

DRUG

Remodulin (treprostinil sodium)

Sponsors & Collaborators

  • Asian Clinical Trials

    collaborator UNKNOWN

  • United Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michael Wade, Ph.D. · United Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00494533 on ClinicalTrials.gov